2. Academic Validation
  3. The role of EZH2 as a potential therapeutic target in retinoblastoma

The role of EZH2 as a potential therapeutic target in retinoblastoma

  • Exp Eye Res. 2023 Jan 18;227:109389. doi: 10.1016/j.exer.2023.109389.
Yuqing Zhao 1,  Ying Cheng 1,  Yi Qu 2
Affiliations

Affiliations

  • 1 Department of Geriatric Medicine, Qilu Hospital of Shandong University, China; Key Laboratory of Cardiovascular Proteomics of Shandong Province, Jinan, China; Jinan Clinical Research Center for Geriatric Medicine, 202132001, China.
  • 2 Department of Geriatric Medicine, Qilu Hospital of Shandong University, China; Key Laboratory of Cardiovascular Proteomics of Shandong Province, Jinan, China; Jinan Clinical Research Center for Geriatric Medicine, 202132001, China. Electronic address: yiqucn@sdu.edu.cn.
PMID: 36669714 DOI: 10.1016/j.exer.2023.109389
Abstract

Enhancer of zeste homolog 2 (EZH2) has been reported selectively expressed in postnatal human retinoblastoma (RB). While, the contribution of EZH2 in progression of RB and its clinical importance has not been clarified. Here, immunohistochemistry (IHC) was performed on tumor specimens from 53 RB patients. UNC1999 and GSK503, inhibitors targeting EZH2, were incubated with human RB cell line WERI-Rb-1 and Y79 to assess the role and mechanism of EZH2 in RB proliferation, metastasis and tumor glycolysis. Administration of UNC1999 in subcutaneous tumor model of RB was conducted. The results showed that highly expressed EZH2 in RB tissues was significantly associated with the poor overall survival. UNC1999 and GSK503 inhibited proliferation, migration, invasion and tumor glycolysis of RB. Results in mouse xenograft model confirmed the inhibitory effect of UNC1999 on tumor growth of RB and the regulation effect of EZH2 to STAT3/FoxO1 signaling pathway. Therefore, EZH2 is rewarding to study as a potential target for anti-RB treatment.

Keywords

EZH2; FoxO1; Prognostic analysis; Retinoblastoma; STAT3; Tumor glycolysis.

Figures
Products